Xilio Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
XLO$8.53-5.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
4. Property and Equipment, Net
Property and equipment, net consists of the following as of December 31, 2025 and 2024:
| December 31, · December 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Laboratory equipment | $ | 6,381 | $ | 5,911 |
| Computers and software | — | 183 | ||
| Furniture and fixtures | 681 | 681 | ||
| Leasehold improvements | 5,124 | 5,124 | ||
| Construction in process | 459 | — | ||
| Total property and equipment | 12,645 | 11,899 | ||
| Less: accumulated depreciation | (8,753) | (7,427) | ||
| Property and equipment, net | $ | 3,892 | $ | 4,472 |
The Company incurred depreciation and amortization expense related to property and equipment of $1.5 million and $1.6 million for years ended December 31, 2025 and 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.